Another phase 2, open-label study assessed the efficacy and safety of olaparib in 23 advanced pancreatic cancer patients with confirmed genetic BRCA1 or BRCA2 mutations (NCT01078662) [35]. This evidence concerns the gene BRCA2 and pancreatic neoplasm.